Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-101 and Rituximab in B-cell Associated Autoimmune Diseases
NCT06581562Phase 1Recruiting
- Sponsor
- IRIS Research and Development
- Start
- May 2024
- Primary completion
- Jul 2027
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zabalafin in rheumatoid arthritis (RA), pemphigus vulgaris (PV), granulomatosis with polyangiitis (GPA) and 2 more (4 arms), sponsored by IRIS Research and Development. Primary endpoints: Incidence of adverse events and relationship to study drug at 104 weeks, Incidence of Serious Adverse Events (SAE) and causality assessment at 104 weeks and 1 more. Started May 2024; status: recruiting.
02
Drugs
zabalafin
03
Conditions
rheumatoid arthritis (RA)pemphigus vulgaris (PV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06581562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581562.